Skip to main content

Table 1 Antimicrobial activity of omadacycline against Gram-positive cocci organisms

From: Antimicrobial activity of omadacycline in vitro against bacteria isolated from 2014 to 2017 in China, a multi-center study

Organism/organism group (number of isolates) Number (cumulative %) of isolates at MIC (mg/L) of: MIC50 MIC90 %S %R
<0.03 0.03 0.06 0.12 0.25 0.5 1 2
Staphylococcus aureus(197) 0 (0.0) 1 (0.5) 43 (22.3) 118 (82.2) 27 (95.9) 5 (98.5) 2 (99.5) 1 (100.0) 0.12 0.25 98.5a 0.5
  Methicillin-susceptible (100) 0 (0.0) 1 (1.0) 27 (28.0) 69 (97.0) 2 (99.0) 1 (100.0)    0.12 0.12 100.0 0.0
  Methicillin-resistant (97)    16 (16.5) 49 (67.0) 25 (92.8) 4 (96.9) 2 (99.0) 1 (100.0) 0.12 0.25 96.9 1.0
  Tetracycline-resistant (116) 0 (0.0) 1 (0.9) 19 (17.2) 67 (75.0) 21 (93.1) 5 (97.4) 2 (99.1) 1 (100.0) 0.12 0.25 97.4 0.9
  Tigecycline-non-susceptible (1)    0 (0.0) 1 (100.0)        100.0 0.0
Enterococcus spp. (25) 0 (0.0) 13 (52.0) 7 (80.0) 5 (100.0)      0.03 0.12   
  Enterococcus faecalis (9) 0 (0.0) 2 (22.2) 4 (66.7) 9 (100.0)      0.06   100.0 0.0
  Enterococcus faecium (16) 0 (0.0) 11 (68.8) 3 (87.5) 2 (100.0)      0.03 0.12   
Streptococcus pneumoniae (59) 6 (10.2) 21 (45.8) 27 (91.5) 3 (96.6) 2 (100.0)     0.06 0.06 96.6 0.0
  Penicillin-susceptible (25) 3 (12.0) 8 (44.0) 11 (88.0) 1 (92.0) 2 (100.0)     0.06 0.12 92.0 0.0
  Penicillin-intermediate (15) 1 (6.7) 6 (46.7) 7 (93.3) 1 (100.0)      0.06 0.06 100.0 0.0
  Penicillin-resistant (19) 2 (10.5) 7 (47.3) 9 (94.7) 1 (100.0)      0.06 0.06 100.0 0.0
  Tetracycline-resistant (53) 4 (7.5) 18 (41.5) 26 (90.6) 3 (96.2) 2 (100.0)     0.06 0.06 96.2 0.0
  Tigecycline-non-susceptible (3) 0 (0.0) 1 (33.3) 0 (33.3) 0 (33.3) 2 (100.0)     0.25   33.3 0.0
Viridans group streptococci (25) 14 (56) 8 (88.0) 1 (92.0) 1 (96.0) 1 (100.0)     0.015 0.06   
  Streptococcus anginosus group (21) 11 (52.4 7 (85.7) 1 (90.5) 1 (95.2) 1 (100.0)     0.015 0.06 95.2 0.0
  Tetracycline-resistant (14) 5 (35.7) 7 (85.7) 1 (92.9) 1 (100.0)      0.03 0.06 100.0 0.0
  Tigecycline-non-susceptible (1)     0 (0.0) 1 (100.0)       0.0 0.0
β-haemolytic streptococci (27) 1 (3.7) 11 (44.4) 6 (66.7) 8 (96.3) 1 (100.0)     0.06 0.12   
  Tetracycline-resistant (20) 1 (5.0) 4 (25.0) 6 (55.0) 8 (95.0) 1 (100.0)     0.06 0.12   
  Streptococcus pyogenes (8) 1 (12.5) 7 (100.0)        0.03   100.0 0.0
  1. a Applying FDA identified breakpoints for ABSSSIs